Skip to main content
Log in

Recommendations to improve identification of hereditary and familial colorectal cancer in Europe

  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

Familial colorectal cancer (CRC) accounts for 10–15% of all CRCs. In about 5% of all cases, CRC is associated with a highly penetrant dominant inherited syndrome. The most common inherited form of non-polyposis CRC is the Lynch syndrome which is responsible for about 2–4% of all cases. Surveillance of individuals at high risk for CRC prevents the development of advanced CRC. About 1 million individuals in Western Europe are at risk for Lynch syndrome. We performed a survey to evaluate the strategies currently used to identify individuals at high risk for CRC in 14 Western European countries. Questionnaires were distributed amongst members of a European collaborative group of experts that aims to improve the prognosis of families with hereditary CRC. The survey showed that in all countries obtaining a family history followed by referral to clinical genetics centres of suspected cases was the main strategy to identify familial and hereditary CRC. In five out of seven countries with a (regional or national) CRC population screening program, attention was paid in the program to the detection of familial CRC. In only one country were special campaigns organized to increase the awareness of familial CRC among the general population. In almost all countries, the family history is assessed when a patient visits a general practitioner or hospital. However, the quality of family history taking was felt to be rather poor. Microsatellite instability testing (MSI) or immunohistochemical analysis (IHC) of CRC are usually recommended as tools to select high-risk patients for genetic testing and are performed in most countries in patients suspected of Lynch syndrome. In one country, IHC was recommended in all new cases of CRC. In most countries there are no specific programs on cancer genetics in the teaching curriculum for medical doctors. In conclusion, the outcome of this survey and the discussions within an European expert group may be used to improve the strategies to identify individuals at high risk of CRC. More attention should be given to increasing the awareness of the general population of hereditary CRC. Immunohistochemical analysis or MSI-analysis of all CRCs may be an effective tool for identifying all Lynch syndrome families. The cost-effectiveness of this approach should be further evaluated. All countries with a CRC population screening program should obtain a full family history as part of patient assessment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mecklin JP (1987) Frequency of hereditary colorectal carcinoma. Gastroenterology 93(5):1021–1025

    CAS  PubMed  Google Scholar 

  2. Ponz de Leon M, Sassatelli R, Sacchetti C, Zanghieri G, Scalmati A, Roncucci L (1989) Familial aggregation of tumors in the three-year experience of a population-based colorectal cancer registry. Cancer Res 49(15):4344–4348

    CAS  PubMed  Google Scholar 

  3. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P et al (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352(18):1851–1860

    Article  CAS  PubMed  Google Scholar 

  4. Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348(10):919–932

    Article  CAS  PubMed  Google Scholar 

  5. Vasen HF, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I et al (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44(6):353–362

    Article  CAS  PubMed  Google Scholar 

  6. de Jong AE, Vasen HF (2006) The frequency of a positive family history for colorectal cancer: a population-based study in the Netherlands. Neth J Med 64(10):367–370

    PubMed  Google Scholar 

  7. Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5):829–834

    Article  CAS  PubMed  Google Scholar 

  8. de Jong AE, Hendriks YM, Kleibeuker JH, de Boer SY, Cats A, Griffioen G et al (2006) Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130(3):665–671

    Article  PubMed  Google Scholar 

  9. Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J et al (2006) Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med 355(18):1863–1872

    Article  CAS  PubMed  Google Scholar 

  10. Vasen HF, Moslein G, Alonso A, Aretz S, Bernstein I, Bertario L et al (2008) Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57(5):704–713

    Article  CAS  PubMed  Google Scholar 

  11. Umar A, Boland CR, Terdiman JP, Syngal S, de la CA, Ruschoff J et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268

    Article  CAS  PubMed  Google Scholar 

  12. van Dijk DA, Oostindier MJ, Kloosterman-Boele WM, Krijnen P, Vasen HF (2007) Family history is neglected in the work-up of patients with colorectal cancer: a quality assessment using cancer registry data. Fam Cancer 6(1):131–134

    Article  PubMed  Google Scholar 

  13. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH et al (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296(12):1507–1517

    Article  CAS  PubMed  Google Scholar 

  14. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349(3):247–257

    Article  CAS  PubMed  Google Scholar 

  15. de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, Griffioen G et al (2004) Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 109(3):468–471

    Article  CAS  PubMed  Google Scholar 

  16. Overbeek LI, Ligtenberg MJ, Willems RW, Hermens RP, Blokx WA, Dubois SV et al (2008) Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol 32(8):1246–1251

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H. F. A. Vasen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vasen, H.F.A., Möslein, G., Alonso, A. et al. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Familial Cancer 9, 109–115 (2010). https://doi.org/10.1007/s10689-009-9291-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-009-9291-3

Keywords

Navigation